

DAY ONE – Wednesday 10th May

TIME	MIN	TOPIC	SPEAKER
14.00 – 14.30	30	Early arrivals – Informal meet for tea and cake	AMMF Team <i>Pre-function Room</i>
14.30 – 14.35	5	Introduction to the Co-chairs and the afternoon sessions	Helen Morement CEO – AMMF
THE MULTIDISCIPLINARY TEAM			
14.35 – 14.40	5	Introduction to the session	Professor John Bridgewater <i>UCL Cancer Institute University College Hospital London</i> Professor Lorenza Rimassa <i>Humanitas University and IRCCS Humanitas Research Hospital, Milan</i>
14.40 – 15.20	40	MDT Presentation and Discussions	Professor Shahid A Khan Professor Rob Goldin Mr Hassan Z Malik Professor Juan Valle Dr Ganesh Radhakrishna Louise Jones/Margaret Griffin
15.20 – 15.35	15	<i>Question Time</i>	<i>MDT Panel Moderated by Co-chairs</i>

MDT Presentation and Discussions

Whilst this session is open to all – patients, carers, healthcare professionals, clinical nurse specialists – its primary objective is to help patients and carers better understand the work, purpose, and importance of an experienced multi disciplinary team (MDT) in confirming the diagnosis and treatment pathway for those with cholangiocarcinoma. All are welcome to submit questions to the panel following the presentation.

* Please note: Poster + Exhibitor Halls are intended for HCPs only.

Times shown are GMT. For CET +1 hour.

TIME	MIN	TOPIC	SPEAKER
ADVOCACY VIEWPOINT			
15.35 – 15.40	5	Introduction to the Work of Advocacy Groups	Professor John Bridgewater Professor Lorenza Rimassa
15.40 – 16.30	10	APiC, Italian Association of cholangiocarcinoma patients	Paolo Leonardi <i>Founder and President</i>
	10	The Japan Cholangiocarcinoma Association (The Daisy Association)	Masako Watanabe <i>Founder</i>
	10	The Cholangiocarcinoma Foundation, Thailand	Dr Ruengsin Thennadee – TBC <i>Chair</i>
	10	Cholangiocarcinoma Foundation, USA	Stacie C. Lindsey <i>Founder & CEO</i>
	10	AMMF, The Cholangiocarcinoma Charity, UK	Helen Morement <i>Founder & CEO</i>
16.30 – 16.45	15	<i>Question Time</i>	<i>Advocacy panel Moderated by Co-chair</i>
16.45 – 16.50	5	End of Day One	Co-chairs / Helen Morement
16.50 – 18.30	100	<i>Break and Networking</i>	
17.00 – 18.00	60	CNS Q+A	<i>Patient / Carer lecture room</i>
18.30 onwards		<i>Meet and Mingle Buffet</i>	
20.00 – 21.00	60	AMMF Clinical/Medical Advisors Board Meeting	Room 7 <i>Invitation Only</i>

Day 1 Programme correct as at 11.04.2023

Programme continued overleaf

DAY TWO – Thursday, 11th May – Morning Session

TIME	MIN	TOPIC	SPEAKER
08.00 – 08.30	30	<i>Registration and Coffee</i>	
08.30 – 08.45	15	Co-Chairs Welcome	Professor John Bridgewater <i>UCL Cancer Institute University College Hospital London</i> Professor Lorenza Rimassa <i>Humanitas University and IRCCS Humanitas Research Hospital, Milan</i>
08.45 – 09.00	15	Overview of AMMF's Work/ External Projects	Helen Morement <i>CEO – AMMF</i>
09.00 – 09.20	20	CCA Overview	Professor Shahid A Khan <i>Imperial College London</i>
09.20 – 09.40	20	CCA Data Project overview	Dr Sophie Jose, <i>Health Data Insight CIC</i>
09.40 – 09.50	10	<i>Question Time</i>	<i>Panel</i>
09.50 – 10.05	15	Patient Perspective	Judith Neptial
10.05 – 10.20	15	<i>Coffee and Networking</i>	
INNOVATION IN PERSONALISED MEDICINE			
10.20 – 10.25	05	Introduction to the session	Professor John Bridgewater Professor Lorenza Rimassa
10.25 – 10.45	20	Molecular profiling in the UK and Europe (what is it, mutations in CCA, etc.)	Dr Heinz-Josef Klumpen <i>Amsterdam UMC, University of Amsterdam Cancer Center Amsterdam, The Netherlands</i>

TIME	MIN	TOPIC	SPEAKER
10.45 – 11.05	20	Personalised medicine – what is it and where are we with CCA. Is this the future?	Professor Juan Valle <i>University of Manchester and The Christie</i>
11.05 – 11.20	15	<i>Question Time</i>	<i>Panel</i>
INNOVATION IN THE TREATMENT LANDSCAPE			
11.20 – 11.25	05	Introduction to the session	Professor John Bridgewater Professor Lorenza Rimassa
11.25 – 11.45	20	Liquid Biopsy and the Access Program	Dr Naureen Starling <i>The Royal Marsden</i>
11.45 – 12.05	20	ERCP Services and CCA	Dr Chris Wadsworth <i>Imperial College Healthcare NHS Trust</i>
12.05 – 12.25	20	Centres of Expertise – what are they, why are they so needed in CCA	Mr Hassan Z Malik <i>Liverpool University Hospitals NHS Foundation trust</i>
12.25 – 12.40	15	<i>Question Time</i>	<i>Panel</i>
12.40 – 13.40	60	<i>Lunch and Networking</i>	
12.55 – 13.40	45	Poster board discussions	Room 12

* Please note: Poster + Exhibitor Halls are intended for HCPs only.
Times shown are GMT. For CET +1 hour.

Programme continued overleaf

DAY TWO – Thursday, 11th May – Afternoon Session

TIME	MIN	TOPIC	SPEAKER
INNOVATION IN THE TREATMENT LANDSCAPE (continued)			
13.40 – 13.45	05	Introduction to the afternoon session	Professor John Bridgewater Professor Lorenza Rimassa
13.45 – 14.05	20	Optimising surgical treatment of biliary tract cancer	Professor John Primrose <i>University of Southampton</i>
14.05 – 14.25	20	Updates on the Surgical Management of Cholangiocarcinoma	Ms Rachel Guest <i>Royal Infirmary of Edinburgh</i>
14.25 – 14.40	15	<i>Question Time</i>	<i>Panel</i>
14.40 – 14.55	15	<i>Tea and Networking</i>	
PARALLEL SESSION – PATIENT AND CARER PRESENTATION <i>Patient/Carer Lecture Room</i>			
14.55 – 15.25	30	Health-Related Quality of Life Measurement Strategy for Solid Rare Cancers	Catarina Simões Padilla <i>Netherlands Cancer Institute, The Netherlands</i>
INNOVATION IN THE TREATMENT LANDSCAPE (continued)			
14.55 – 15.25	15	Industry	<i>TBC (HCPs only)</i>
	15	Industry	<i>TBC (HCPs only)</i>
15.25 – 15.45	20	PSC + CCA The Aspirin Trial	Dr Simon Rushbrook <i>University of East Anglia</i> Professor Shahid A Khan <i>Imperial College London</i>
15.45 – 16.05	20	SIRT – A treatment for CCA?	Dr Julien Edeline <i>Centre Eugène Marquis, Rennes, France</i>

TIME	MIN	TOPIC	SPEAKER
16.05 – 16.20	15	<i>Question Time</i>	<i>Panel</i>
INTERNATIONAL ASPECTS OF CCA			
16.20 – 16.25	05	Introduction to the session	Professor John Bridgewater Professor Lorenza Rimassa
16.25 – 16.45	20	The Professor Narong Khuntikeo Memorial Lecture	Professor Ross Andrews <i>Khon Kaen University, Thailand and Imperial College London</i>
16.45 – 17.05	20	The OV diagnosis test system	Professor Paiboon Sithithaworn <i>Khon Kaen University, Thailand</i>
17.05 – 17.25	20	Europe – Viewpoint from Spain	Dr Angela Lamarca <i>Fundacion Jimenez Diaz University Hospital, Madrid</i>
17.25 – 17.45	20	The CCA Landscape in Ireland	Professor Maeve Lowery <i>Trinity College, Dublin</i>
17.45 – 18.05	20	Circular RNAs in Cholangiocarcinoma	Dr Kefei Yuan <i>Laboratory of Liver Surgery, West China Hospital, Sichuan University, China</i>
18.05 – 18.20	15	<i>Question Time</i>	<i>International Panel</i>
18.20 – 18.25	5	End of Day Two	Professor John Bridgewater Professor Lorenza Rimassa
18.25 – 19.45	60	<i>Networking</i>	
18.25 – 19.10	45	Global CCA Alliance	Room 7 – Invitation Only
18.40 – 19.25	45	Poster boards	Room 12
19.45 – 21.45	120	<i>Buffet Dinner</i>	

* Please note: Poster + Exhibitor Halls are intended for HCPs only.
Times shown are GMT. For CET +1 hour.

Day 2 Programme correct as at 11.04.2023

Programme continued overleaf

DAY THREE – Friday, 12th May – Morning Session

TIME	MIN	TOPIC	SPEAKER
08.00 – 08.50	50	Cholangiocarcinoma UK Committee Meeting	Room 7 <i>Invitation only</i>
08.15 – 09.00	45	<i>Welcome Coffee</i>	
09.00 – 09.10	10	Welcome to Day 3	Professor John Bridgewater <i>UCL Cancer Institute University College Hospital London</i> Professor Lorenza Rimassa <i>Humanitas University and IRCCS Humanitas Research Hospital, Milan</i>
CCA SPECIALIST GROUP UPDATES			
09.10 – 09.30	20	ENS-CCA – Overview and update	Dr Chiara Braconi <i>Chair – ENS-CCA</i>
09.30 – 09.50	20	CCA-UK – Overview and update	Professor Shahid A Khan <i>Chair – CCA-UK</i>
09.50 – 10.00	10	<i>Question time</i>	<i>Panel</i>
BIG DATA			
10.00 – 10.05	05	Introduction to the session	Dr Shirin Elizabeth Khorsandi <i>Kings College, London</i> Dr Tim Kendall <i>University of Edinburgh</i>
10.05 – 10.25	20	Molecular data: Implications of genomics in cholangiocarcinoma	Professor B Jesper Andersen <i>University of Copenhagen, Denmark</i>

TIME	MIN	TOPIC	SPEAKER
10.25 – 10.45	20	How can AI inform physician's decisions?	Dr Julien Calderaro <i>Henri Mondor University Hospital, France</i>
10.45 – 11.05	20	Exploring Protein Kinase CK2 inhibition and identifying new targets	Professor Kevin Gaston <i>University of Nottingham</i>
11.05 – 11.20	15	<i>Question time</i>	<i>Panel</i>
11.20 – 11.35	15	<i>Coffee and Networking</i>	
NOVEL FINDINGS IN CCA RESEARCH			
11.35 – 11.40	05	Introduction to the session	Professor John Bridgewater Professor Lorenza Rimassa
11.40 – 11.55	15	The role of normal cholangiocytes in regulating cholangiocarcinoma cells during co-culture	Gemma Owen <i>University of Oxford</i>
11.55 – 12.10	15	KLF5 upregulation is a common event in cholangiocarcinoma, acting as an oncogene and constituting a bad prognostic factor	Dr Pedro M. Rodrigues <i>Biodonostia Health Research Institute, Spain</i>
12.10 – 12.25	15	A Notch signalling niche drives the initiation and early growth of cholangiocarcinoma	Dr Anabel Martinez Lyons <i>University Of Edinburgh</i>
12.25 – 12.50	25	<i>Question Time</i>	<i>Panel</i>
12.50 – 13.05	15	Patient Perspective	Francesca Clementi
13.05 – 14.05	60	<i>Lunch and Networking</i>	

* Please note: Poster + Exhibitor Halls are intended for HCPs only.
Times shown are GMT. For CET +1 hour.

Programme continued overleaf

DAY THREE – Friday, 12th May – Afternoon Session

TIME	MIN	TOPIC	SPEAKER
TRANSLATION INTO CLINICAL PRACTICE			
14.05 – 14.10	05	Introduction to the afternoon session	Professor John Bridgewater Professor Lorenza Rimassa
14.10 – 14.30	20	The ENSCCA clinical database: current status, studies and new results	Professor Jesus Bañales <i>Biodonostia Institute, Spain</i>
14.30 – 14.50	20	Biomarkers from the BILCAP series: Focus on HER2	Dr Valerie Crolley <i>University College Hospital London</i>
14.50 – 15.10	20	Acquired resistance to FGFR inhibitors	Dr Daniel DiToro <i>Massachusetts, USA: Brigham and Women's Hospital, Boston Massachusetts General Hospital, Boston Ragon Institute of MGH, MIT and Harvard, Cambridge Harvard Medical School, Boston</i>
15.10 – 15.25	15	<i>Question Time</i>	<i>Panel</i>
15.25 – 15.35	10	<i>Tea and Networking</i>	

TIME	MIN	TOPIC	SPEAKER
WORKSHOP ON PRECLINICAL MODELS			
15.35 – 15.40	05	Introduction to the session	Dr Chiara Braconi <i>Beatson West of Scotland Cancer Centre</i>
15.40 – 16.00	20	Characterisation of a precision cut tumour slice model to explore cholangiocarcinoma	Dr Laura Randle <i>Liverpool John Moores University and The University of Liverpool</i>
16.00 – 16.20	20	Novel genetically engineered mouse models of cholangiocarcinoma	Professor Jen Morton <i>Cancer Research UK Beatson Institute</i>
16.20 – 16.35	15	<i>Question time</i>	<i>Panel</i>
HIGHLIGHTS OF THE CONFERENCE			
16.35 – 16.45	10	Conference highlights	Professor John Bridgewater Professor Lorenza Rimassa
16.55		<i>Conference Close</i>	